

801
가
5
papillary adenocarcinoma, well and moderately differentiated tubular adenocarcinoma differentiated carcinoma (DC), poorly differentiated carcinoma, signet ring cell carcinoma, mucinous carcinoma undifferentiated carcinoma (UDC)
가 . 2001
12 31 47±29
(3 113) 97.4% (780/801)
가
Kaplan-Meier
log rank test
SPSS 9.0 for Window Program (SPSS Inc. Chicago, Illinois, U.S.A.) P 0.05

1)
Borrmann 2 가 가
Borrmann 4 가
가 (Table 1).

Table 1. Clinicopathologic features

Variables	DC (n=313)	UDC (n=488)	P value
Age (yr)			
Mean ± SD	59.8 ± 10.1	52.6 ± 12.0	0.000
≤ 57	118 (38)	295 (60)	
> 57	195 (62)	193 (40)	0.000
Sex			
Male	224 (72)	286 (59)	
Female	89 (28)	202 (41)	0.000
Location			
Lower 1/3	204 (65)	230 (47)	
Middle 1/3	89 (28)	198 (40)	
Upper 1/3	19 (6)	47 (10)	
Whole	1 (1)	13 (3)	0.000
Gastrectomy			
Subtotal	263 (84)	321 (66)	
Total	50 (16)	167 (34)	0.000
Gross type			
Early cancer			
Elevated	56 (37)	29 (21)	
Depressed	96 (63)	107 (79)	0.004
Advanced cancer			
Borrmann 1	8 (5)	6 (2)	
Borrmann 2	35 (22)	43 (12)	
Borrmann 3	117 (72)	258 (73)	
Borrmann 4	1 (1)	45 (13)	0.000
Size (cm)			
Mean ± SD	4.7 ± 2.6	6.2 ± 3.3	0.000
≤ 5	194 (62)	230 (47)	
> 5	119 (38)	258 (53)	0.000
Stage of disease			
I	178 (57)	169 (34)	
II	45 (14)	75 (16)	
III	61 (20)	147 (30)	
IV	29 (9)	97 (20)	0.000
Lymphatic permeation			
Absent	151 (48)	167 (33)	
Present	162 (52)	321 (67)	0.000
Vascular permeation			
Absent	275 (88)	421 (86)	
Present	38 (12)	67 (14)	NS
Perineural invasion			
Absent	307 (98)	469 (96)	
Present	6 (2)	19 (4)	NS
Site of recurrence			
Peritoneum	15 (27)	73 (57)	
Liver	16 (29)	7 (6)	
Hung/bone/brain	5 (8)	20 (15)	
Loco-regional	20 (36)	29 (22)	0.000

DC = differentiated carcinoma; UDC = undifferentiated carcinoma; NS = not significant; Numbers in parentheses are percentages.

Table 3. Univariate survival analysis for clinicopathologic variables

Variables	No	5-YSR (%)	P value
Age (yr)			
57	413	79.0	
>57	388	64.3	0.0000
Sex			
Male	510	70.4	
Female	291	75.4	NS
Location			
Lower 1/3	434	73.7	
Middle 1/3	287	75.8	
Upper 1/3	66	52.4	
Whole	14	40.8	0.0000
Gastrectomy			
Subtotal	584	79.4	
Total	217	53.0	0.0000
EGC			
Elevated	85	89.3	
Depressed	202	96.1	NS
AGC			
Borrmann 1	14	57.7	
Borrmann 2	78	84.9	
Borrmann 3	375	57.4	
Borrmann 4	46	33.0	0.0000
Size (cm)			
5	424	82.3	
>5	377	60.9	0.0000
Stage			
I	347	93.7	
II	120	85.9	
III	208	52.5	
IV	126	31.5	0.0000
Lymphatic permeation			
Absent	318	89.3	
Present	483	60.6	0.0000
Venous permeation			
Absent	696	76.1	
Present	105	45.2	0.0000
Perineural invasion			
Absent	776	73.2	
Present	24	45.5	0.0002
Histologic type			
DC	313	77.4	
UDC	488	69.1	0.0045

5-YSR = 5-year survival rate; DC = differentiated carcinoma; UDC = undifferentiated carcinoma; NS = not significant.

Table 4. Multivariate survival analysis

Variables	Exp (B)	95% CI	P value
Age			
57 yr	1		0.0000
>57 yr	2.2496	1.6742 3.0228	
Site			
Lower 1/3	1		0.0148
Middle 1/3	0.9130	0.6635 1.2564	
Upper 1/3	1.8686	1.2195 2.8633	
Whole	1.1608	0.5521 2.4407	
Size			
5 cm	1		0.9078
>5 cm	1.0189	0.7420 1.3992	
Stage			
I	1		0.0000
II	3.4843	1.7777 6.8292	
III	11.2110	5.9898 20.9833	
IV	25.6326	13.2216 49.6937	
Lymphatic invasion	1.3905	0.8719 2.2174	0.1662
Venous invasion	0.6963	0.4978 0.9742	0.0346
Neural invasion	0.9787	0.5670 1.6895	0.9385
Histology			
DC	1		0.5620
UDC	1.1000	0.7971 1.5178	

EXP (B) = exponential beta coefficient; CI = confidence interval; DC = differentiated carcinoma; UDC = undifferentiated carcinoma.

Table 5. Recurred cases among early gastric cancer patients

No	Age/sex	Depth	Node	Histology	Recur site
1.	61/female	Submucosa	4/65	DC	liver
2.	49/male	Submucosa	0/28	DC	liver
3.	58/male	Submucosa	0/76	DC	liver
4.	69/male	Submucosa	0/52	DC	lung
5.	71/male	Submucosa	0/31	DC	Virchow's node
6.	56/male	Submucosa	1/34	DC	lung
7.	66/male	Mucosa	0/19	DC	lung
8.	60/male	Mucosa	0/32	UDC	lung

DC = differentiated carcinoma; UDC = undifferentiated carcinoma.

5)

가	152	7 (4.6%)	287	135
		1 (0.7%)		

Table 6. Five-year survival rate according to stage and histologic type in gastric cancer patients who received postoperative chemotherapy

Stages	DC % (number)	UDC % (number)	P value
I	86 (27)	97 (39)	NS
II	89 (38)	89 (70)	NS
III	58 (54)	52 (138)	NS
IV	23 (25)	36 (92)	NS
All cases	66 (144)	61 (339)	NS

DC = differentiated carcinoma; UDC = undifferentiated carcinoma; NS = not significant.

8 6 가 , 2 가
8 2 .
7
1 가 Virchow (Table 5).
5 14 162 가 49
352 128
가 (19 ,
39%) (73 , 57%) .
6) ()
313 46% 144 , 488
69% 339 (5-fluorou-
racil, epirubicin, cisplatin, methotrexate, and leucovorin)
(doxifluridine) 가
5
(Table 6).

가
가 , ,
가 , ,
(5-8)
Nakamura (9) ,
, diffusely infiltrative
tumor ulcerating infiltrative tumor
97% 69% .
(57),
, , , ,
가

가
Nakamura 45 (98%), 3
375 258 (69%)가
352 162
152 136
Adachi (10)
Noda (8)
5 74% 60% , Riberio
(3) 5 44% 28%
Davessar (11) Lauren
가 가
Adachi (4) ,
()
Maehara (12) Haraguchi (13)
Borrmann 4 ,
가
가
Borrmann 4 , 가
Adachi (14) 가
(15) Moriguchi
Adachi
가
(4) 가
가 (P=0.0261)
가
가 8 2
(6) 가 . Maehara (16,17)
가
, pyrimidine nucleotide
3
가

가

가

가

가

REFERENCES

- 1) Siewert JR, Bottcher K, Stein HJ, Roder JD. German gastric carcinoma study group. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. *Ann Surg* 1998;228:449-61.
- 2) Nakamura K, Ueyama T, Yao T, Xuan ZX, Ambe K, Adachi Y. Pathology and prognosis of gastric carcinoma: findings in 10,000 patients who underwent primary gastrectomy. *Cancer* 1992;70:1030-7.
- 3) Ribeiro MM, Sarmiento JA, Simoes MAS, Bastos J. Prognostic significance of Lauren and Ming classification and other pathologic parameters in gastric carcinoma. *Cancer* 1981;47:780-4.
- 4) Adachi Y, Yasuda K, Inomata M, Sato K, Shiraishi N, Kitano S. Pathology and prognosis of gastric carcinoma: well versus poorly differentiated type. *Cancer* 2000;89:1418-24.
- 5) Lauren P. The two histologic main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma: an attempt at a histo-clinical classification. *Acta Pathol Microbiol Scand* 1965;64:31-49.
- 6) Ming SC. Gastric carcinoma: a pathological classification. *Cancer* 1977;39:2475-85.
- 7) Sugano H, Nakamura K, Kato Y. Pathological studies of human gastric cancer. *Acta Pathol Jpn (Suppl 2)* 1982;32:329-47.
- 8) Noda S, Soejima K, Inokuchi K. Clinicopathological analysis of the intestinal type and diffuse type of gastric carcinoma. *Jpn J Surg* 1980;10:277-83.
- 9) Nakamura K, Ueyama T, Yao T, Xuan ZX, Ambe K, Adachi Y, et al. Pathology and prognosis of gastric carcinoma: findings in 10,000 patients who underwent primary gastrectomy. *Cancer* 1992;70:1030-7.
- 10) Adachi Y, Mori M, Enjoji M, Sugimachi K. Microvascular architecture of early gastric carcinoma: microvascular-histopathologic correlates. *Cancer* 1993;72:32-6.
- 11) Davessar K, Pezzullo JC, Kessimian N, Hale JH, Jauregui HO. Gastric adenocarcinoma: prognostic significance of several pathologic parameters and histologic classifications. *Hum Pathol* 1990;21:325-32.
- 12) Maehara Y, Moriguchi S, Orita H, Kakeji Y, Haraguchi M, Korenaga D. Lower survival rate for patients with carcinoma of the stomach of Borrmann type IV after gastric resection. *Surg Gynecol Obstet* 1992;175:13-6.
- 13) Haraguchi M, Watanabe A, Kakeji Y, Tsujitani S, Baba H, Maehara Y. Prognostic significance of serosal invasion in carcinoma of the stomach. *Surg Gynecol Obstet* 1991;172:29-32.
- 14) Adachi Y, Kamakura T, Mori M, Baba H, Maehara Y, Sugimachi K. Prognostic significance of the number of positive lymph nodes in gastric carcinoma. *Br J Surg* 1994;81:414-6.
- 15) Moriguchi S, Maehara Y, Korenaga D, Kakeji Y, Sugimachi K, Nose Y. The relationship between prognostic significance of pathological type and the degree of gastric wall invasion in gastric cancer. *Cancer J* 1992;5:220-3.
- 16) Maehara Y, Anai H, Kusumoto H, Sugimachi K. Poorly differentiated human gastric carcinoma is more sensitive to anti-tumor drugs than is well differentiated carcinoma. *Eur J Surg Oncol* 1987;13:203-6.
- 17) Maehara Y, Kusumoto T, Sakaguchi Y, Kusumoto H, Kido Y, Anai H. Pyrimidine nucleotide synthesis is more extensive in poorly differentiated than in well-differentiated human gastric carcinoma. *Cancer* 1989;63:96-101.